Patents by Inventor ETSUKO YASUDA

ETSUKO YASUDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RSV-SPECIFIC BINDING MOLECULE
    Publication number: 20210277094
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: June 18, 2020
    Publication date: September 9, 2021
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20200325213
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 15, 2020
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULE
    Publication number: 20200317754
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 8, 2020
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-specific binding molecules and means for producing them
    Patent number: 10730931
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 4, 2020
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • RSV-specific binding molecule
    Patent number: 10723786
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: July 28, 2020
    Assignee: MedImmune, Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULE
    Publication number: 20190040120
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: July 27, 2018
    Publication date: February 7, 2019
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20180327484
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: July 23, 2018
    Publication date: November 15, 2018
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • RSV-specific binding molecules and means for producing them
    Patent number: 10059757
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: August 28, 2018
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • RSV-specific binding molecule
    Patent number: 10035843
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: July 31, 2018
    Assignee: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV G protein specific antibodies
    Patent number: 10017562
    Abstract: The invention relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The invention further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 10, 2018
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Etsuko Yasuda
  • RSV G PROTEIN SPECIFIC ANTIBODIES
    Publication number: 20170342134
    Abstract: The invention relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The invention further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Application
    Filed: June 30, 2017
    Publication date: November 30, 2017
    Inventors: Tim Beaumont, Etsuko Yasuda
  • RSV G protein specific antibodies
    Patent number: 9718876
    Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: August 1, 2017
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULE
    Publication number: 20160251412
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: February 12, 2016
    Publication date: September 1, 2016
    Applicant: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20160244509
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: February 18, 2016
    Publication date: August 25, 2016
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • RSV-specific binding molecules and means for producing them
    Patent number: 9321831
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 26, 2016
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • RSV specific binding molecule
    Patent number: 9283274
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 15, 2016
    Assignee: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV G PROTEIN SPECIFIC ANTIBODIES
    Publication number: 20150004155
    Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Application
    Filed: November 16, 2012
    Publication date: January 1, 2015
    Applicant: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20140377279
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: December 25, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • RSV SPECIFIC BINDING MOLECULE
    Publication number: 20140093500
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 3, 2014
    Applicant: MEDIMMUNE LIMITED
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20140072575
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 13, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda